
LIVMARLI® Global Availability
The first approved treatment for cholestatic pruritus in patients with Alagille syndrome (ALGS) globally. See where LIVMARLI is now approved.*
*Approval through country regulatory agencies; commercialized by Mirum or partner/distributor.
United States
Cholestatic pruritus in ALGS three months and older
Prescribing Information and Important Safety InformationEuropean Union
Cholestatic pruritus in ALGS two months and older
SMPCCanada
Cholestatic pruritus in ALGS
- Pediatrics (12 months to 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of LIVMARLI in these pediatric patients have been established. Therefore, Health Canada has authorized an indication for pediatric use.
- Pediatrics (<12 months): The safety and efficacy of LIVMARLI in these pediatric patients have not been established.
China1
Cholestatic pruritus in ALGS one year
and older
Israel2
Cholestatic pruritus in ALGS one year
and older
South Korea3
Cholestatic pruritus in ALGS one year
and older
1. Approved through country regulatory agencies; commercialized by partner, CANbridge.
2. Approved through country regulatory agencies; commercialized by distributor partner, Neopharm.
3. Approved through country regulatory agencies; commercialized by partner, GC Pharma.

